<DOC>
	<DOCNO>NCT00395876</DOCNO>
	<brief_summary>This Phase III , randomize , double-blind , placebo-controlled study conduct 24 center United States Canada . 100 adult pediatric patient dysfunctional central venous catheter ( CVCs ) randomly assign 1:1 ratio receive initial dose either placebo ( Arm A ) tenecteplase ( Arm B ) .</brief_summary>
	<brief_title>A Study Tenecteplase Restoration Function Dysfunctional Central Venous Catheters</brief_title>
	<detailed_description />
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Clinically stable , opinion investigator CVC occlusion Able fluid infuse volume necessary instill study drug CVC Able 3 mL blood ( patient weigh ≥ 10 kg ) 1 mL blood ( patient weigh &lt; 10 kg ) withdrawn select study CVC follow patient reposition Selected study CVC insert &lt; 2 day prior treatment Selected study CVC know dysfunctional &gt; 7 day Selected study CVC implant specifically hemodialysis ( HD ) Use power injector select study CVC study Evidence mechanical , nonthrombotic occlusion select study CVC ( e.g. , kink catheter suture constrict catheter ) Previously treat study tenecteplase catheter clearance trial Use investigational drug therapy within 28 day prior treatment Use fibrinolytic agent ( e.g. , alteplase , tenecteplase , reteplase , urokinase ) within 24 hour prior treatment Known pregnant breastfeeding screen CVC know suspected infection History intracranial hemorrhage , aneurysm , arteriovenous malformation Use heparin ( unfractionated low molecular weight ) within 24 hour prior treatment , except use intermittent lowdose , continuous infusion heparin maintain catheter vessel patency Use warfarin within 7 day prior treatment , except lowdose warfarin use prophylaxis Initiation increase dose Plavix® ( clopidogrel bisulfate ) within 7 day prior treatment At high risk bleed event embolic complication ( i.e. , recent pulmonary embolus , deep vein thrombosis , endarterectomy , clinically significant righttoleft shunt ) opinion investigator , know condition bleed constitutes significant hazard Known hypersensitivity tenecteplase component formulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>TNKase</keyword>
	<keyword>CVA</keyword>
	<keyword>CVAD</keyword>
	<keyword>Central venous access catheter</keyword>
	<keyword>CVA catheter</keyword>
</DOC>